|
EP3321277B1
(en)
|
2007-07-10 |
2019-09-18 |
Apogenix AG |
Tnf superfamily collectin fusion proteins
|
|
EP2540740B1
(en)
*
|
2008-06-17 |
2014-09-10 |
Apogenix GmbH |
Multimeric TNF receptors
|
|
WO2010006772A2
(en)
*
|
2008-07-14 |
2010-01-21 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Use of cd95 inhibitors for the treatment of inflammatory disorders
|
|
EP2310509B1
(en)
|
2008-07-21 |
2015-01-21 |
Apogenix GmbH |
Tnfsf single chain molecules
|
|
JP5844158B2
(ja)
|
2009-01-09 |
2016-01-13 |
アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングApogenix GmbH |
三量体形成融合タンパク質
|
|
TWI476001B
(zh)
|
2011-12-26 |
2015-03-11 |
Ind Tech Res Inst |
三倍體Fc融合蛋白及其用途
|
|
JP6373836B2
(ja)
|
2012-07-26 |
2018-08-15 |
ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド |
多量体融合タンパク質ワクチン及び免疫療法
|
|
WO2014100913A1
(en)
*
|
2012-12-24 |
2014-07-03 |
Beijing Anxinhuaide Biotech. Co., Ltd |
Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
|
|
NO2776305T3
(OSRAM)
|
2014-04-23 |
2018-01-27 |
|
|
|
BR102014031185A8
(pt)
*
|
2014-12-12 |
2021-05-04 |
Fund De Amparo A Pesquisa Do Estado De Sao Paulo Fapesp |
proteína recombinante indutora da apoptose; processo de obtenção da dita proteína e o seu uso no tratamento do câncer
|
|
DK3247728T3
(da)
|
2015-01-20 |
2020-07-13 |
Igm Biosciences Inc |
Tumornekrosefaktor-(tnf)-superfamiliereceptorbindende molekyler og anvendelser deraf
|
|
MA41460A
(fr)
|
2015-02-03 |
2017-12-12 |
Oncomed Pharm Inc |
Agents de liaison à la tnfrsf et leurs utilisations
|
|
EP3076179A1
(en)
|
2015-03-30 |
2016-10-05 |
Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts |
Diagnosis and treatment of low grade gliomas
|
|
CA2999116A1
(en)
|
2015-09-23 |
2017-03-30 |
Apogenix Ag |
Anti-cd95l antibody
|
|
EP3374504B1
(en)
*
|
2015-11-09 |
2025-03-19 |
CureVac SE |
Optimized nucleic acid molecules
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
US20200121719A1
(en)
|
2017-01-06 |
2020-04-23 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
|
|
WO2018129336A1
(en)
|
2017-01-06 |
2018-07-12 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
|
CA3062874A1
(en)
|
2017-05-10 |
2018-11-16 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
US11819517B2
(en)
|
2017-06-05 |
2023-11-21 |
Iovance Biotherapeutics, Inc. |
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
|
|
EP3664832B1
(en)
*
|
2017-08-11 |
2023-10-18 |
The Board of Trustees of the University of Illinois |
Truncated guinea pig l-asparaginase variants and methods of use
|
|
JP7557367B2
(ja)
|
2017-11-17 |
2024-09-27 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
細針吸引及び小生検からのtil拡大培養
|
|
CA3083118A1
(en)
|
2017-11-22 |
2019-05-31 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
|
JP7565795B2
(ja)
|
2017-12-15 |
2024-10-11 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球の有益な投与を決定するシステム及び方法並びにその使用方法、並びに腫瘍浸潤リンパ球の有益な投与及びその使用方法
|
|
BR112020013848A2
(pt)
|
2018-01-08 |
2020-12-01 |
Iovance Biotherapeutics, Inc. |
métodos para expandir linfócitos infiltrantes de tumor e para tratar um indivíduo com câncer, população de linfócitos infiltrantes de tumor, e, método para avaliar fatores de transcrição
|
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
|
CA3090795A1
(en)
|
2018-02-13 |
2019-08-22 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
|
|
SG11202009170UA
(en)
|
2018-03-29 |
2020-10-29 |
Iovance Biotherapeutics Inc |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
CN112368003A
(zh)
|
2018-04-27 |
2021-02-12 |
艾欧凡斯生物治疗公司 |
肿瘤浸润淋巴细胞的基因编辑及其在免疫治疗中的用途
|
|
WO2019217753A1
(en)
|
2018-05-10 |
2019-11-14 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
US20220275043A1
(en)
|
2018-07-17 |
2022-09-01 |
Massachusetts Institute Of Technology |
Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
|
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療
|
|
MX2021002887A
(es)
|
2018-09-20 |
2021-06-04 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes de tumores (tils) a partir de muestras de tumor crioconservadas.
|
|
JOP20210094A1
(ar)
|
2018-11-05 |
2023-01-30 |
Iovance Biotherapeutics Inc |
عمليات لإنتاج الخلايا الليمفاوية للورم الارتشاحي واستخداماتها في العلاج المناعي
|
|
BR112021008549A2
(pt)
|
2018-11-05 |
2022-01-04 |
Iovance Biotherapeutics Inc |
Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor
|
|
WO2020096927A1
(en)
|
2018-11-05 |
2020-05-14 |
Iovance Biotherapeutics, Inc. |
Expansion of tils utilizing akt pathway inhibitors
|
|
EP3877512A2
(en)
|
2018-11-05 |
2021-09-15 |
Iovance Biotherapeutics, Inc. |
Selection of improved tumor reactive t-cells
|
|
EP3898949A1
(en)
|
2018-12-19 |
2021-10-27 |
Iovance Biotherapeutics, Inc. |
Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
|
|
AU2020233284A1
(en)
|
2019-03-01 |
2021-09-16 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
BR112021019328A2
(pt)
|
2019-03-29 |
2021-11-30 |
Myst Therapeutics Llc |
Métodos ex vivo para produzir um produto terapêutico de célula t e composições e métodos relacionados
|
|
US20220249559A1
(en)
|
2019-05-13 |
2022-08-11 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
JP2022553389A
(ja)
|
2019-10-25 |
2022-12-22 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球の遺伝子編集及び免疫療法におけるその使用
|
|
CA3162703A1
(en)
|
2019-11-27 |
2021-06-03 |
Myst Therapeutics, Llc |
Method of producing tumor-reactive t cell composition using modulatory agents
|
|
CA3161104A1
(en)
|
2019-12-11 |
2021-06-17 |
Cecile Chartier-Courtaud |
Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
|
|
AU2021226903A1
(en)
|
2020-02-27 |
2022-10-20 |
Turnstone Biologics Corp. |
Methods for ex vivo enrichment and expansion of tumor reactive T cells and related compositions thereof
|
|
TW202208616A
(zh)
|
2020-05-04 |
2022-03-01 |
美商艾歐凡斯生物治療公司 |
改良之腫瘤反應性t細胞的選擇
|
|
US20230172987A1
(en)
|
2020-05-04 |
2023-06-08 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
IL300632A
(en)
*
|
2020-08-24 |
2023-04-01 |
Sanofi Pasteur Inc |
Vaccines against SARS-COV-2 infections
|
|
US20230372397A1
(en)
|
2020-10-06 |
2023-11-23 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
TW202241468A
(zh)
|
2020-12-11 |
2022-11-01 |
美商艾歐凡斯生物治療公司 |
用腫瘤浸潤性淋巴球療法與braf抑制劑及/或mek抑制劑組合治療癌症患者
|
|
WO2022133140A1
(en)
|
2020-12-17 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
|
EP4262827A1
(en)
|
2020-12-17 |
2023-10-25 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocytes
|
|
EP4288140A1
(en)
|
2021-02-05 |
2023-12-13 |
Iovance Biotherapeutics, Inc. |
Adjuvant therapy for cancer
|
|
WO2022187741A2
(en)
|
2021-03-05 |
2022-09-09 |
Iovance Biotherapeutics, Inc. |
Tumor storage and cell culture compositions
|
|
JP2024515189A
(ja)
|
2021-04-19 |
2024-04-05 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
細胞免疫療法におけるキメラ共刺激受容体、ケモカイン受容体、及びそれらの使用
|
|
EP4340850A1
(en)
|
2021-05-17 |
2024-03-27 |
Iovance Biotherapeutics, Inc. |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
US20240254193A1
(en)
*
|
2021-05-27 |
2024-08-01 |
Bejing Anxinhuaide Biotech, Co., Ltd |
A super-trail molecule comprising two trail trimers
|
|
WO2023009716A1
(en)
|
2021-07-28 |
2023-02-02 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
|
CA3232700A1
(en)
|
2021-09-24 |
2023-03-30 |
Rafael CUBAS |
Expansion processes and agents for tumor infiltrating lymphocytes
|
|
CA3235824A1
(en)
|
2021-10-27 |
2023-05-04 |
Frederick G. Vogt |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
|
EP4430167A1
(en)
|
2021-11-10 |
2024-09-18 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
|
US20250101380A1
(en)
|
2022-01-28 |
2025-03-27 |
Iovance Biotherapeutics, Inc. |
Tumor infiltrating lymphocytes engineered to express payloads
|
|
EP4507704A1
(en)
|
2022-04-15 |
2025-02-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
|
EP4565683A1
(en)
|
2022-08-01 |
2025-06-11 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
WO2024151885A1
(en)
|
2023-01-13 |
2024-07-18 |
Iovance Biotherapeutics, Inc. |
Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
|
|
WO2025101484A1
(en)
|
2023-11-06 |
2025-05-15 |
Iovance Biotherapeutics, Inc. |
Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
|